Last reviewed · How we verify
Rivaroxaban 2.5mg
Rivaroxaban 2.5mg, marketed by Asan Medical Center, holds a position in the anticoagulant market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established mechanism and indication, though specific details are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Rivaroxaban 2.5mg |
|---|---|
| Also known as | Xarelto 2.5mg, EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047 |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (PHASE4)
- Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (PHASE3)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes? (PHASE4)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Thromboprophylaxis in Lower Limb Immobilisation (PHASE3)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban 2.5mg CI brief — competitive landscape report
- Rivaroxaban 2.5mg updates RSS · CI watch RSS
- Asan Medical Center portfolio CI